文献速递新发突发、热带与寄生虫病细菌感染、耐药与抗菌药物

阿奇霉素与伊维菌素社区群体给药控制疥疮与脓疱疮的随机试验

Randomized Trial of Community Treatment With Azithromycin and Ivermectin Mass Drug Administration for Control of Scabies and Impetigo.
PubMed 文献 · Clin Infect Dis · 2019-01-01

六社区随机接受伊维菌素群体给药或伊维菌素联合阿奇霉素群体给药,基线及12个月时疥疮与脓疱疮患病率在两组均下降且降幅相近,脓疱疮皮损中化脓性链球菌比例显著下降,联合组3个月时出现暂时性大环内酯耐药金黄色葡萄球菌增加。

要点

  • 伊维菌素联合阿奇霉素与单用伊维菌素相比,疥疮和脓疱疮患病率降幅相似。
  • 群体给药后脓疱疮皮损中化脓性链球菌比例显著下降(63% vs 23%,P < .01)。
  • 阿奇霉素群体给药后3个月出现暂时性大环内酯耐药金黄色葡萄球菌增加(53%,8/15),12个月时未检出(0/13)。

核心结论

  • 阿奇霉素与伊维菌素联合群体给药与单用伊维菌素相比,疥疮和脓疱疮患病率降幅相似。
  • 群体给药后脓疱疮皮损中化脓性链球菌比例下降。
  • 阿奇霉素群体给药后出现暂时性大环内酯耐药金黄色葡萄球菌比例增加。

研究设计与样本

  • 六个社区随机接受伊维菌素群体给药或伊维菌素联合阿奇霉素群体给药。
  • 基线及12个月时测量疥疮和脓疱疮患病率。
  • 基线、3个月和12个月时采集脓疱疮皮损拭子检测抗菌药物耐药。

主要发现

  • 基线时,单用伊维菌素组疥疮和脓疱疮患病率分别为11.8%和10.1%,联合治疗组分别为9.2%和12.1%。
  • 12个月时,单用伊维菌素组疥疮和脓疱疮患病率分别降至1.0%和2.5%,联合治疗组分别降至0.7%和3.3%。
  • 检出金黄色葡萄球菌的脓疱疮皮损比例无变化(基线80% vs 12个月86%;组间无显著差异)。
  • 检出化脓性链球菌的脓疱疮皮损比例显著下降(63% vs 23%,P < .01)。
  • 3个月时,联合治疗组53%(8/15)的金黄色葡萄球菌分离株对大环内酯类耐药,12个月时未检出耐药株(0/13)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Scabies is a public health problem in many countries, with impetigo and its complications important consequences. Ivermectin based mass drug administration (MDA) reduces the prevalence of scabies and, to a lesser extent, impetigo. We studied the impact of co-administering azithromycin on the prevalence of impetigo and antimicrobial resistance. METHODS: Six communities were randomized to receive either ivermectin-based MDA or ivermectin-based MDA co-administered with azithromycin. We measured scabies and impetigo prevalence at baseline and 12 months. We collected impetigo lesions swabs at baseline, 3 and 12 months to detect antimicrobial resistance. RESULTS: At baseline, scabies and impetigo prevalences were 11.8% and 10.1% in the ivermectin-only arm and 9.2% and 12.1% in the combined treatment arm. At 12 months, the prevalences had fallen to 1.0% and 2.5% in the ivermectin-only arm and 0.7% and 3.3% in the combined treatment arm. The proportion of impetigo lesions containing Staphylococcus aureus detected did not change (80% at baseline vs 86% at 12 months; no significant difference between arms) but the proportion containing pyogenic streptococci fell significantly (63% vs 23%, P < .01). At 3 months, 53% (8/15) of S. aureus isolates were macrolide-resistant in the combined treatment arm, but no resistant strains (0/13) were detected at 12 months. CONCLUSIONS: Co-administration of azithromycin with ivermectin led to similar decreases in scabies and impetigo prevalence compared to ivermectin alone. The proportion of impetigo lesions containing pyogenic streptococci declined following MDA. There was a transient increase in the proportion of macrolide-resistant S. aureus strains following azithromycin MDA. CLINICAL TRIALS REGISTRATION: clinicaltrials.gov (NCT02775617).

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Marks M, Toloka H, Baker C, et al. Randomized Trial of Community Treatment With Azithromycin and Ivermectin Mass Drug Administration for Control of Scabies and Impetigo. Clin Infect Dis. 2019. PMID: 29985978. doi:10.1093/cid/ciy574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。